{"id":"NCT04143217","sponsor":"Supernus Pharmaceuticals, Inc.","briefTitle":"Open-label Long-Term Safety and Efficacy of SPN-812 (Viloxazine Extended-release Capsule) in Adults With ADHD","officialTitle":"An Open-Label Extension Study to Evaluate the Long-Term Safety and Efficacy of SPN-812 (Viloxazine Extended-release Capsule) in Adults With Attention-Deficit/Hyperactivity Disorder","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2020-01-23","primaryCompletion":"2022-07-26","completion":"2022-12-14","firstPosted":"2019-10-29","resultsPosted":"2024-02-13","lastUpdate":"2024-02-13"},"enrollment":159,"design":{"allocation":"NA","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Attention-Deficit/Hyperactivity Disorder"],"interventions":[{"type":"DRUG","name":"SPN-812","otherNames":["viloxazine extended-release capsules (Qelbree)"]}],"arms":[{"label":"Open-Label Treatment","type":"EXPERIMENTAL"}],"summary":"Open label, flexible dose, long-term multicenter study of safety and efficacy of SPN-812 in adult ADHD patients","primaryOutcome":{"measure":"Incidence of Adverse Events","timeFrame":"Up to 156 weeks","effectByArm":[{"arm":"Open-Label Treatment","deltaMin":72.3,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":38,"countries":["United States"]},"refs":{"pmids":["39373844"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":2,"n":159},"commonTop":["Insomnia","Nausea","Headache","Fatigue","Corona virus infection"]}}